$45.27 Billion in Sales Expected for AmerisourceBergen Corp. (NYSE:ABC) This Quarter

Equities research analysts forecast that AmerisourceBergen Corp. (NYSE:ABC) will post $45.27 billion in sales for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for AmerisourceBergen’s earnings, with estimates ranging from $45.05 billion to $45.60 billion. AmerisourceBergen reported sales of $43.14 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 4.9%. The firm is expected to report its next quarterly earnings report on Thursday, August 1st.

According to Zacks, analysts expect that AmerisourceBergen will report full-year sales of $178.90 billion for the current financial year, with estimates ranging from $176.54 billion to $180.08 billion. For the next financial year, analysts expect that the company will report sales of $188.08 billion, with estimates ranging from $186.19 billion to $190.88 billion. Zacks’ sales calculations are a mean average based on a survey of research firms that follow AmerisourceBergen.

AmerisourceBergen (NYSE:ABC) last released its earnings results on Thursday, May 2nd. The company reported $2.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.15. AmerisourceBergen had a return on equity of 46.24% and a net margin of 0.53%. The business had revenue of $43.32 billion for the quarter, compared to analyst estimates of $43.44 billion. During the same quarter last year, the firm posted $1.94 earnings per share. The business’s revenue was up 5.6% compared to the same quarter last year.

Several brokerages have recently commented on ABC. TheStreet upgraded AmerisourceBergen from a “c+” rating to a “b” rating in a research note on Tuesday, February 19th. Zacks Investment Research upgraded AmerisourceBergen from a “hold” rating to a “buy” rating and set a $89.00 price target on the stock in a research note on Wednesday. ValuEngine lowered AmerisourceBergen from a “hold” rating to a “sell” rating in a research note on Monday, February 25th. Argus cut their price target on AmerisourceBergen from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, June 3rd. Finally, Bank of America lowered AmerisourceBergen from a “buy” rating to an “underperform” rating and cut their price target for the company from $95.00 to $76.00 in a research note on Wednesday, April 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $88.33.

Shares of AmerisourceBergen stock traded down $1.39 during trading on Friday, hitting $85.05. 1,003,820 shares of the stock traded hands, compared to its average volume of 1,460,872. The firm has a market cap of $17.94 billion, a P/E ratio of 13.10, a P/E/G ratio of 1.65 and a beta of 0.92. The company has a current ratio of 0.95, a quick ratio of 0.56 and a debt-to-equity ratio of 1.43. AmerisourceBergen has a 52-week low of $69.36 and a 52-week high of $94.88.

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 3rd. Investors of record on Monday, May 20th were given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 1.88%. The ex-dividend date of this dividend was Friday, May 17th. AmerisourceBergen’s payout ratio is currently 24.65%.

In other AmerisourceBergen news, insider Dale Danilewitz sold 543 shares of the firm’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $78.77, for a total value of $42,772.11. Following the completion of the sale, the insider now owns 2,171 shares of the company’s stock, valued at $171,009.67. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Robert P. Mauch sold 24,767 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $81.16, for a total value of $2,010,089.72. Following the completion of the sale, the executive vice president now directly owns 43,286 shares of the company’s stock, valued at approximately $3,513,091.76. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 51,563 shares of company stock worth $4,164,135. 27.80% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Acima Private Wealth LLC acquired a new stake in shares of AmerisourceBergen during the fourth quarter worth about $26,000. Rational Advisors LLC raised its position in AmerisourceBergen by 1,627.3% during the first quarter. Rational Advisors LLC now owns 380 shares of the company’s stock valued at $30,000 after acquiring an additional 358 shares in the last quarter. Riverview Trust Co raised its position in AmerisourceBergen by 127.3% during the first quarter. Riverview Trust Co now owns 391 shares of the company’s stock valued at $31,000 after acquiring an additional 219 shares in the last quarter. JNBA Financial Advisors purchased a new position in AmerisourceBergen during the fourth quarter valued at approximately $37,000. Finally, Trust Co. of Vermont raised its position in AmerisourceBergen by 963.8% during the first quarter. Trust Co. of Vermont now owns 500 shares of the company’s stock valued at $40,000 after acquiring an additional 453 shares in the last quarter. 66.56% of the stock is owned by institutional investors and hedge funds.

AmerisourceBergen Company Profile

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers.

Recommended Story: Compound Interest and Why It Matters When Investing

Get a free copy of the Zacks research report on AmerisourceBergen (ABC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AmerisourceBergen (NYSE:ABC)

Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.